Cerus Corporation heads into its August earnings with a striking contradiction: short sellers have rebuilt aggressively over the past month, even as the stock just posted a 21% one-month gain.
The short interest story is the week's dominant tension. Short interest now stands at 10.1% of free float — and that number has nearly doubled since mid-June, when it was running closer to 5.5%. The bulk of that rebuild happened in the final week of June, with short shares jumping from roughly 11 million to over 20 million in a matter of days. Despite a small daily pullback on July 9, the weekly change is essentially flat, meaning those new short positions are holding firm at current price levels. Days to cover at 4.1 suggests it would take shorts nearly a week of average volume to unwind, adding a degree of squeeze risk if a catalyst materialises.
The lending market tells a different story, and it's an important counterpoint. Borrow is not tight at all — availability is running at over 2,200%, meaning there are more than 22 shares available to lend for every one already borrowed. That is comfortably above even the 52-week low of 457%. Cost to borrow has actually eased over the past month, falling 24% to just 0.41% — a level that implies almost no premium for the right to short. What this means is that the short build has been easy and cheap to put on, with no squeeze pressure in the infrastructure of the lending market. Options reinforce a broadly bullish lean: the put/call ratio is running at 0.097, well below its 20-day average of 0.109, and sitting near the low end of its 52-week range. There is more call open interest than at almost any point in the past year relative to puts.
On the Street, the picture is constructively but quietly bullish — and somewhat stale. All three analysts covering CERS carry buy-equivalent ratings. BTIG upgraded to Buy in early May with a $4.00 target, which remains the most recent action. Other coverage from Cantor Fitzgerald and Craig-Hallum also sits at Overweight and Buy respectively, though those notes date back to 2024 and should be treated as historical context rather than fresh conviction. The mean target near $4.00 implies roughly 28% upside from current levels at $3.12, which is meaningful but not extreme for a small-cap biotech. Factor scores are mixed: EPS surprise ranks in just the 18th percentile, and EPS momentum over the past 30 days is near the bottom of the universe at the 2nd percentile — the Street has been revising estimates down, not up. The short score of 55.4, while not alarming, has eased slightly from 57.8 at end of June, suggesting modest de-escalation in bearish conviction over the week.
The institutional ownership picture adds a notable layer. ARK Investment Management holds 9.6% of shares and added nearly 961,000 shares through June 30 — a material top-up from a fund that tends to signal longer-term growth conviction. BlackRock added 681,000 shares over the same period, now holding 10.8%. Soleus Capital built an entirely new position of 10.8 million shares as of March 31, accounting for 5.4% of the company. Against that accumulation, recent insider activity is a mild caution flag: the CEO, CFO, COO, and Chief Legal Officer all sold shares at $2.94 on June 30, realising a combined ~$595,000 in proceeds. These were paired with stock award grants on the same day, a pattern consistent with sell-to-cover on restricted stock vesting — but the cluster of C-suite selling immediately ahead of a 6% post-earnings decline in early June is worth noting in context.
The earnings history gives this setup genuine bite. The most recent print on June 2 produced a 6.3% single-day drop and a 9.2% five-day decline — the note filed at the time pointed to missed guidance on blood safety product adoption and extended hospital procurement cycles. The print before that, on April 30, was the opposite: a 41.7% single-day surge and 36% gain over five days. That kind of volatility around results, with the next event scheduled for August 3, is the frame within which the current short rebuild makes most sense — bears are positioning for a repeat of the June miss rather than another April surprise.
With August 3 now the focal point, the question for the next few weeks is whether the hospital procurement data flowing through Q2 supports the adoption trajectory bulls are paying for, or whether the June miss was a leading indicator of a structural slowdown — and that tension, between cheap-to-borrow short conviction and institutional accumulation at the same price level, is what makes CERS worth watching closely into the print.
See the live data behind this article on ORTEX.
Open CERS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
